The United States represents a significant market for deferasirox, driven by the growing prevalence of transfusion-dependent blood disorders such as thalassemia, sickle cell disease, and myelodysplastic syndromes. The country benefits from a well-established healthcare infrastructure, advanced diagnostic capabilities, and strong access to specialized hematology treatments. Increasing awareness...